KR20120051603A - 항카드헤린 항체 - Google Patents

항카드헤린 항체 Download PDF

Info

Publication number
KR20120051603A
KR20120051603A KR1020117028845A KR20117028845A KR20120051603A KR 20120051603 A KR20120051603 A KR 20120051603A KR 1020117028845 A KR1020117028845 A KR 1020117028845A KR 20117028845 A KR20117028845 A KR 20117028845A KR 20120051603 A KR20120051603 A KR 20120051603A
Authority
KR
South Korea
Prior art keywords
antibody
asp
leu
val
thr
Prior art date
Application number
KR1020117028845A
Other languages
English (en)
Korean (ko)
Inventor
히로유키 아브라타니
리린 쟝
케이스케 이시이
카스시 코우다
아야 사카모토
케이코 카스미
히로시 오니시
요코 카유카와
Original Assignee
고쿠리츠다이가쿠호징 도쿄다이가쿠
가부시키가이샤 페르세우스 프로테오믹스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠다이가쿠호징 도쿄다이가쿠, 가부시키가이샤 페르세우스 프로테오믹스 filed Critical 고쿠리츠다이가쿠호징 도쿄다이가쿠
Publication of KR20120051603A publication Critical patent/KR20120051603A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020117028845A 2009-05-01 2010-04-30 항카드헤린 항체 KR20120051603A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPJP-P-2009-111834 2009-05-01
JP2009111834 2009-05-01
JP2010018416 2010-01-29
JPJP-P-2010-018416 2010-01-29

Publications (1)

Publication Number Publication Date
KR20120051603A true KR20120051603A (ko) 2012-05-22

Family

ID=43032279

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117028845A KR20120051603A (ko) 2009-05-01 2010-04-30 항카드헤린 항체

Country Status (8)

Country Link
US (3) US8455249B2 (de)
EP (1) EP2426149A4 (de)
JP (1) JP5723270B2 (de)
KR (1) KR20120051603A (de)
CN (1) CN102753579A (de)
AU (1) AU2010242338B2 (de)
CA (1) CA2760642A1 (de)
WO (1) WO2010126137A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906492A2 (pt) * 2008-01-11 2015-12-01 Synovex Corp antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações
WO2011099524A1 (ja) 2010-02-10 2011-08-18 富士フイルムＲｉファーマ株式会社 放射性金属標識抗カドヘリン抗体
AU2011319777B2 (en) * 2010-10-27 2016-12-08 The Research Foundation For The State University Of New York Compositions targeting the soluble extracellular domain of E-cadherin and related methods for cancer therapy
ES2690469T3 (es) * 2010-10-29 2018-11-21 Perseus Proteomics Inc. Anticuerpo anti-CDH3 que tiene alta capacidad de internalización
US9127061B2 (en) 2011-06-24 2015-09-08 Perseus Proteomics Inc. Anti-human P-cadherin (CDH3) recombinant antibody
KR20140138956A (ko) * 2012-03-15 2014-12-04 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 Ｅ-카드헤린의 세포외 도메인의 저해제를 포함하는 병용 치료법
EP2957632B1 (de) * 2013-02-15 2020-09-30 Perseus Proteomics Inc. Humanisierter anti-cdh3-antikörper, arzneimittelkonjugat daraus und verwendung davon
EP3164417A1 (de) 2014-07-01 2017-05-10 Pfizer Inc. Bispezifische heterodimere diabodies und verwendungen davon
WO2016075670A1 (en) 2014-11-14 2016-05-19 Novartis Ag Antibody drug conjugates
PT3283524T (pt) 2015-04-17 2023-06-05 Amgen Res Munich Gmbh Construções de anticorpos biespecíficos para cdh3 e cd3
WO2017008169A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
CA1247538A (en) 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US5286647A (en) 1982-05-21 1994-02-15 University Of California Human-human hybridomas for neoplasms
US4618577A (en) 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (de) 1991-09-23 1999-06-23 Medical Research Council Methoden zur Herstellung humanisierter Antikörper
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0656941B1 (de) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995000143A1 (en) 1993-06-24 1995-01-05 Leiras Oy Composition for ophthalmic use
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (de) 1993-12-03 1996-09-18 Medical Research Council Rekombinante indungsproteine und -peptide
US6048972A (en) 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
AU2002310222A1 (en) * 2001-05-31 2002-12-09 Chiron Corporation P-cadherin as a target for anti-cancer therapy
US20040247555A1 (en) * 2002-10-15 2004-12-09 Eli Sprecher Methods of and compositions for modulating hair growth via P-cadherin modulators
EP1560597A4 (de) * 2002-10-29 2007-06-27 Pharmacia Corp Differentiell ausgedrückte krebsgene, dabei kodierte polypeptide und verfahren zu ihrer verwendung
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
JP2009528257A (ja) 2006-02-28 2009-08-06 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体のエフェクター機能を用いて細胞を障害する方法
WO2008121160A2 (en) 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
KR20100132998A (ko) * 2008-04-04 2010-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 종양 성장, 혈관신생 및 전이를 차단하는 것을 목표로 하는 암에 대한 항체

Also Published As

Publication number Publication date
EP2426149A1 (de) 2012-03-07
EP2426149A4 (de) 2013-01-23
WO2010126137A1 (ja) 2010-11-04
AU2010242338A1 (en) 2011-12-01
JP5723270B2 (ja) 2015-05-27
CN102753579A (zh) 2012-10-24
US20120136140A1 (en) 2012-05-31
US9017683B2 (en) 2015-04-28
US8455249B2 (en) 2013-06-04
JPWO2010126137A1 (ja) 2012-11-01
US20130245232A1 (en) 2013-09-19
AU2010242338B2 (en) 2013-12-19
US20130243771A1 (en) 2013-09-19
CA2760642A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
KR20120051603A (ko) 항카드헤린 항체
EP3191517B1 (de) Kreuzreaktive siglec-antikörper
SA518390904B1 (ar) مستقبلات مولد مضاد خيمرية تقوم على أجسام مضادة أحادية الحقل وطرق لاستخدامها
CN112566698A (zh) T细胞受体和表达该t细胞受体的工程化细胞
KR20210013165A (ko) GUCY2c에 특이적인 항체 및 이의 용도
CN117586401A (zh) 抗pd-1抗体及其用途
US9127061B2 (en) Anti-human P-cadherin (CDH3) recombinant antibody
US20140234342A1 (en) Nkp46-mediated nk cell tuning
CN110914304A (zh) Cd96抗体、其抗原结合片段及医药用途
TR201808018T4 (tr) Anti-B7-H3 antikoru.
CN114560941B (zh) Cldn18.2的抗体及其应用
CN114206929B (zh) 一种抗tigit免疫抑制剂及应用
EP3323831A1 (de) Monoklonaler anti-aggrus-antikörper, domäne in aggrus, die für die bindung an clec-2 erforderlich ist, und verfahren zum screening auf aggrus-clec-2-bindungsinhibitor
CN110790839A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN113527489A (zh) 抗cd73的抗体及其用途
EP2905335A1 (de) Antikörper gegen menschliches dlk-1 mit in-vivo-antitumorwirkung
US20240050473A1 (en) Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
EP3656794A1 (de) Zusammensetzungen und verfahren zur detektion von krebs
CN112812179B (zh) 高亲和力高特异性抗cmtm6单克隆抗体及其用途
CA3226996A1 (en) Antibodies for treating cancer
CN113831411A (zh) 针对l1cam的单域抗体及其衍生蛋白和应用
US20200024347A1 (en) Or10h1 antigen binding proteins and uses thereof
EP4261228A1 (de) Spezifisch an das strepto-tag ii-tag bindender antikörper und verwendung davon
CN111704668B (zh) 抗ccr4抗体及其在治疗癌症中的应用
CN117025541A (zh) 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid